Neuronetics, Inc. (NRC.F)
| Previous Close | 3.4200 |
| Open | 3.3800 |
| Bid | 2.4050 x 0 |
| Ask | 2.5100 x 0 |
| Day's Range | 3.3800 - 3.3950 |
| 52 Week Range | 0.9420 - 4.4000 |
| Volume | |
| Avg. Volume | 12 |
| Market Cap | 103.725M |
| Beta (5Y Monthly) | 2.44 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9800 |
| Earnings Date | May 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.50 |
GuruFocus.comNeuronetics Inc (STIM) Reports Q1 2024 Earnings: Revenue Surpasses Estimates, Narrowing Losses
Insight into Neuronetics' Financial Health and Strategic Advances
ZacksNeuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
Neuronetics (STIM) delivered earnings and revenue surprises of 18.18% and 1.85%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireNeuronetics Reports Record First Quarter 2024 Financial and Operating Results
MALVERN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2024. First Quarter 2024 Highlights First quarter 2024 revenue of $17.4 million, a 12% increase as compared to the
